Kunze E, Töpfer S, Zöller N
Eur J Cancer Clin Oncol. 1984 May;20(5):711-7. doi: 10.1016/0277-5379(84)90021-x.
The present study deals with the effect of stimulation of urothelial proliferation on experimental bladder carcinogenesis. To induce proliferative activity of the bladder mucosa cyclophosphamide (cp) was intraperitoneally administered to rats in a single dose (100 mg/kg). N-Butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) was used as carcinogen and administered by gavage in 3 fractionated doses when proliferation of the urothelium was highest at 28 and 40 hr as well as 7 days following the injection of cp. Contrary to our original working hypothesis, tumor development proved to be inhibited in the bladder following initial stimulation of urothelial proliferation by cp. After administration of a low total dose of BBN (300 mg/kg) and an experimental period of 6 and 12 months none of the rats pretreated with cp developed a tumor in the regenerating bladder, whereas solitary transitional cell papillomas were observed in 6.7% of the control animals with a quiescent bladder. Following administration of BBN at a high total dose (1.300 mg/kg) and an induction time of 4, 6 and 12 months papillomas and non-invasive papillary transitional cell carcinomas occurred in only 21.6% of the rats initially receiving cp but in 48.1% of the control animals without stimulation of urothelial proliferation by cp. After treatment with BBN alone there was a far larger number of rats with multiple tumors in the quiescent bladder. The reduction in the incidence of tumors following administration of cp is not attributable to a prolongation of the latency period or induction time. It is an open question which mechanisms are responsible for the observed inhibition of experimental bladder carcinogenesis. An increased DNA repair induced synchronously with the stimulated replicative de-novo DNA synthesis or a decreased activity of urothelial enzymes metabolizing BBN to its ultimate carcinogen are proposed as the most likely explanations.
本研究探讨了尿路上皮增殖刺激对实验性膀胱致癌作用的影响。为诱导膀胱黏膜的增殖活性,对大鼠腹腔注射单次剂量的环磷酰胺(CP,100 mg/kg)。使用N-丁基-N-(4-羟丁基)亚硝胺(BBN)作为致癌物,在注射CP后28小时、40小时以及7天尿路上皮增殖最高时,分3次灌胃给予。与我们最初的工作假设相反,事实证明,CP最初刺激尿路上皮增殖后,膀胱肿瘤的发生受到抑制。给予低总剂量的BBN(300 mg/kg)并经过6个月和12个月的实验期后,预先接受CP处理的大鼠在再生膀胱中均未发生肿瘤,而在膀胱静止的对照动物中,有6.7%观察到孤立的移行细胞乳头状瘤。给予高总剂量的BBN(1300 mg/kg)并经过4个月、6个月和12个月的诱导期后,最初接受CP处理的大鼠中仅有21.6%发生乳头状瘤和非侵袭性乳头状移行细胞癌,而未用CP刺激尿路上皮增殖的对照动物中有48.1%发生。单独用BBN处理后,膀胱静止的大鼠中出现多个肿瘤的数量要多得多。给予CP后肿瘤发生率的降低并非归因于潜伏期或诱导期的延长。目前尚不清楚是哪些机制导致了观察到的实验性膀胱致癌作用的抑制。最有可能的解释是,与受刺激的复制性从头DNA合成同步诱导的DNA修复增加,或尿路上皮将BBN代谢为其最终致癌物的酶活性降低。